State and Public School Life and Health Insurance Board Quality of Care Sub-Committee Minutes March 3, 2010

The State and Public Life and Health Insurance Board, Quality of Care Committee met on March 3, 2010 at 1:00 p.m. in the EBD Board Room, 501 Woodlane, Little Rock, Arkansas.

Members Present

Scott Pace
Dr. William Golden
Caryol Hendricks
Dr. Michael Moody/Proxy
Shelby McCook
Steve Madigan

Members Absent

Dr. Joseph Thompson Ray Montgomery Carol Shockley Renee Mallory Frazier Edwards

Jason Lee, Executive Director, Employee Benefits Division, DFA

Others Present

Peggy Starling, AFMC; George Platt, Amy Tustison, Sherri Saxby, Ellen Justus, Shannon Roberts, Donna Cook, Lori Eden, Florence Marvin, Tracy Collins, Latryce Taylor, Cathy Harris, EBD; Bryan Meldrum, Nova Sys; Ronda Walthal, Wayne Whitley, AHTD; Barbara Melugin, Health Advantage; Shonda Rocke, Informed Rx

CALL TO ORDER

The meeting was called to order by Scott Pace, Chairman.

APPROVAL OF MINUTES

The request was made by Pace to approve minutes from the January 13, 2010 meeting. Hendricks made the motion to approve. Dr. Golden seconded. All were in favor. Minutes approved.

BENEFITS STRATEGIC PLANNING WORKGROUP

RECOMMENDATION (BSPW) by George Platt, Chairman

Platt reported Medicare & Medicaid Services (CMS) are developing a list of proposed clinical measures for hospital and professionals. Platt said the plan has always used the Medicare and Medicaid guidelines and suggested they utilize the quality measure as well.

Platt presented one recommendation for committee consideration.

Recommendation: To adopt the soon-to-be-approved list of Medicare & Medicaid clinical quality performances measures for both providers and hospitals.

A discussion ensued.

Platt said the workgroup will bring back a list of the proposed subset measures at the next quality meeting; assuming the final list has been determined by CMS.

McCook made the motion to accept recommendation. Hendricks seconded the motion. All were in favor. Motion carried.

QUALITY COMMITTEE PACKET by Jason Lee, EBD Director Lee presented the members with a packet to be used as reference for future meetings. Materials in the packet included; previous HEDIS measure reports, sample of analytical data reports, 2010 Schedule of Benefits, preventative care benefits and other information.

Meeting Adjourned.

AGENDA

State and Public School Life
And Health Insurance Board
Quality of Care Sub-Committee
EBD Board Room
501 Building, 5th Floor
1:00 p.m.
March 3, 2010

1.	Call to Order	Scott Pace, Chairman
2.	Approval of Minutes	Scott Pace, Chairman
3.	BSPW Recommendation	George Platt, EBB
4.	Quality Committee Packet	Jason Lee. EBD

Next Meeting May 5, 2010

Mission and Purpose as stated in A.C.A. 21-5-404 12(c) (ii)

The Quality of Care Subcommittee may review and recommend quality performance indicators for use, recommend baseline performance goals, recommend alignment of financial incentives to improve performance, and track improvements in delivery of care.

ARBenefits Health Plan Performance Indicators

In addition to quality indicators such as HEDS measures which measure such clinical elements as breast cancer screenings and diabetes care, I felt that it was also important to share some additional performance indicators of the plan and benchmarks.

Granted, monthly premium comparisons are not a traditional "Quality" indicator, but health insurance is not a single-minded concept. Monthly premium can be an indicator of quality if you consider that high premiums have an impact on lower income employees or employees of relatively good health because those two groups may consider dropping coverage if the base premium is too high. Uninsured employees may go years without routine medical care and preventive screenings only to join the plan in future years when their health has taken a turn for the worse, thereby putting a strain on the overall plan based on their demand for services.

Average Monthly Premium Comparison - POS Plan


2007 – Single 2007 – Family	Kaiser / HRET \$ 361.00 \$ 966.00	ARBenefits Health \$ 329.38 \$ 883.24
2008 – Single 2008 – Family	\$ 387.00 \$ 1,028.00	\$ 372.00 \$ 989.68
2009 – Single 2009 – Family		\$ 400.16 \$ 1,057.48
2010 – Single 2010 – Family	·	\$ 394.17 \$ 1,048.41

Kaiser / HRET numbers are from the 2007 and 2008 (POS Plan Type) Kaiser Family Foundation and Health Research & Education Trust Employer Health Benefits Annual Survey, of which EBD is a contributing survey respondent.

ARBenefits Health rates reflect State Employee Active rates for Health Advantage POS plan option for 2007 and Health Advantage ARHealth plan option for 2008.

2007 - 2009 rates for ARBenefits Health reflect full discount (\$20 single / \$40 family)

Allocation of Premium Dollars - 2008 Plan Year



As you can see from the image above, \$0.69 of every premium dollar is paid in medical claims with \$0.22 paid for pharmacy claims.

Vendor administration fees and Plan administration fees only account for \$0.07 of every dollar spent.

Place of Service - Medical

Of the claim dollars paid during the 2008 plan year for Medical, below is a breakdown of the general type of service and the percentage of paid claims.

	Physicians Fees excluding ancillary	Total Inpatient	Total Outpatient	Total Other
ASE Actives	\$17,453,140.12	\$41,497,556.85	\$35,502,711.79	\$24,587,600.86
PSE Active	\$23,457,455.60	\$56,014,158.90	\$44,955,775.69	\$31,971,803.34
	rio distributo di cita			
ASE Non-Medicare Retiree	\$1,421,964.54	\$4,035,994.83	\$2,875,627.18	\$3,050,123.00
PSE Non-Medicare Retiree	\$1,537,283.59	\$4,364,514.68	\$3,086,046.64	\$2,933,487.04
ASE Medicare Primary Retiree	\$1,961,929.11	\$3,730,301.20	\$3,831,393.66	\$4,503,605.04
PSE Medicare Primary Retiree	\$1,077,615.48	\$1,663,149.34	\$1,945,825.83	\$2,719,539.16
TOTAL	\$46,909,388.44	\$111,305,675.80	\$92,197,380.79	\$69,766,158.44
Percent of Medical paid claims	14.7%	34.8%	28.8%	21.8%

CMS-0033-P 123

TABLE 3: Proposed Clinical Quality Measures for Electronic Submission by Medicare or Medicaid Eligible Professionals for the 2011 and 2012 Payment Year

Measure Number	Clinical Quality Measure Title & Description	Clinical Quality Measure Developer & Contact Information	Electronic Measure Specifications Information	Core/Specialty Measure Group
PQRI I NQF 0059	Title: Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus Description: Percentage of patients aged 18 through 75 years with diabetes mellitus who had most recent hemoglobin A1c greater than 9.0%	National Committee for Quality Assurance (NCQA) Contact Information: www.ncqa.org	http://www.cms.hhs.gov/ PQRI/20 AlternativeRep ortingMechanisms.asp#T opOfPage	Endocrinology, Primary Care
PQRI 2 NQF 0064	Title: Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus Description: Percentage of patients aged 18 through 75 years with diabetes mellitus who had most recent LDL-C level in control (less than 100 mg/dl)	NCQA Contact Information: www.ncqa.org	http://www.cms.hhs.gov/ PQRI/20 AlternativeRep ortingMechanisms.asp#T opOfPage	Endocrinology
PQRI 3 NQF 0061	Title: Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus Description: Percentage of patients aged 18 through 75 years with diabetes mellitus who had most recent blood pressure in control (less than 140/80 mmHg)	NCQA Contact Information: www.ncqa.org	http://www.cms.hhs.gov/ PQRI/20 AlternativeRep ortingMechanisms.asp#T opOfPage	Endocrinology
PQRI 5 NQF 0081	Title: Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) Description: Percentage of patients aged 18 years and older with a diagnosis of heart failure and LVSD who were prescribed ACE inhibitor or ARB therapy	American Medical Association- sponsored Physician Consortium for Performance Improvement (AMA-PCPI) Contact Information: cpe@ama-assn.org	http://www.cms.hhs.gov/ PORI/20_AlternativeRep ortingMechanisms.asp#T opOfPage	Cardiology
PQRI 7 NQF 0070	Title: Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) Description: Percentage of patients aged 18 years and older with a diagnosis of CAD and prior MI who were prescribed beta-blocker therapy	AMA-PCPI Contact Information: cpe@ama-assn.org	http://www.cms.hhs.gov/ PQRI/20_AlternativeRep ortingMechanisms.asp#T opOfPage	Cardiology
PQRI 110 NQF 0041	Title: Preventive Care and Screening: Influenza Immunization for Patients ≥ 50 Years Old Description: Percentage of patients aged 50 years and older who received an influenza immunization during the flu season (September through February)	AMA-PCPI Contact Information: cpe@ama-assn.org	http://www.cms.hhs.gov/ PQRI/20_AlternativeRep ortingMechanisms.asp#T opOfPage	Primary Care

Measure Number	Clinical Quality Measure Title & Description	Clinical Quality Measure Developer & Contact Information	Electronic Measure Specifications Information	Core/Specialty Measure Group
PQRI 111 NQF 0043	Title: Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older Description: Percentage of patients aged 65 years and older who have ever received a pneumococcal vaccine	NCQA Contact Information: www.ncqa.org	http://www.cms.hhs.gov/ PORI/20 AlternativeRep ortingMechanisms.asp#T opOfPage	Pulmonology
PQRI 112 NQF 0031	Title: Preventive Care and Screening: Screening Mammography Description: Percentage of women aged 40 through 69 years who had a mammogram to screen for breast cancer within 24 months	NCQA Contact Information: www.ncqa.org	http://www.cms.hhs.gov/ PQRI/20 AlternativeRep ortingMechanisms.asp#T opOfPage	Oncology, Primary Care, Obstetrics and Gynecology
PQRI 113 NQF 0034	Title: Preventive Care and Screening: Colorectal Cancer Screening Description: Percentage of patients aged 50 through 80 years who received the appropriate colorectal cancer screening	NCQA Contact Information: www.ncqa.org	http://www.cms.hhs.gov/ PQRI/20 AlternativeRep ortingMechanisms.asp#T opOfPage	Oncology, Primary Care, Gastroenterology
PQRI 6 NQF 0067	Title: Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD Description: Percentage of patients aged 18 years and older with a diagnosis of CAD who were prescribed oral antiplatelet therapy	AMA-PCPI Contact Information: cpe@ama-assn.org		Cardiology
PQRI 8 NQF 0083	Title: Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) Description: Percentage of patients aged 18 years and older with a diagnosis of heart failure who also have LVSD and who were prescribed beta-blocker therapy	AMA-PCPI Contact Information: cpe@ama-assn.org		Cardiology
PQRI 9 NQF 0105	Title: Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD Description: Percentage of patients aged 18 years and older diagnosed with new episode of MDD and documented as treated with antidepressant medication during the entire 84-day (12-week) acute treatment phase	NCQA Contact Information: www.ncqa.org		Psychiatry

Measure Number	Clinical Quality Measure Title & Description	Clinical Quality Measure Developer & Contact Information	Electronic Measure Specifications Information	Core/Specialty
PQRI 10	Title: Stroke and Stroke Rehabilitation: Computed Tomography	AMA-PCPI/NCQA	intermation	Measure Group
NQF 0246	(CT) or Magnetic Resonance Imaging (MRI) Reports Description: Percentage of final reports for CT or MRI studies of the brain performed within 24 hours of arrival to the hospital for patients aged 18 years and older with either a diagnosis of ischemic stroke or transient ischemic attack (TIA) or intracranial hemorrhage or at least one documented symptom consistent with ischemic stroke or TIA or intracranial hemorrhage that includes	Contact Information: cpe@ama-assn.org www.ncqa.org		Radiology
	documentation of the presence or absence or each of the following: hemorrhage and mass lesion and acute infarction.	·		
PQRI 12	Title: Primary Open Angle Glaucoma (POAG): Optic Nerve	AMA-PCPI/NCOA		Onhthalmalage
NQF 0086	Evaluation Description: Percentage of patients aged 18 years and older with a diagnosis of POAG who have an optic nerve head evaluation during one or more office visits within 12 months	Contact Information: cpe@ama-assn.org www.ncqa.org		Ophthalmology
PQRI 18	Title: Diabetic Retinopathy: Documentation of Presence or			
NQF 0088	Absence of Macular Edema and Level of Severity of Retinopathy Description: Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed which included documentation of the level of severity of retinopathy and the presence or absence of macular edema during one or more office visits within 12 months	AMA-PCPI/NCQA Contact Information: cpe@ama-assn.org www.ncqa.org		Ophthalmology
PQRI 19	Title: Diabetic Retinopathy: Communication with the Physician	AMA-PCPI/NCOA		Onbthalmalagu
NQF 0089	Managing On-going Diabetes Care Description: Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed with documented communication to the physician who manages the on-going care of the patient with diabetes mellitus regarding the findings of the macular or fundus exam at least once within 12 months	Contact Information: cpe@ama-assn.org www.ncqa.org		Ophthalmology

Measure Number PQRI 20	Clinical Quality Measure Title & Description	Clinical Quality Measure Developer & Contact Information	Electronic Measure Specifications Information	Core/Specialty Measure Group
NQF 0270	Title: Perioperative Care: Timing of Antibiotic Prophylaxis – Ordering Physician Description: Percentage of surgical patients aged 18 years and older undergoing procedures with the indications for prophylactic parenteral antibiotics, who have an order for prophylactic antibiotic to be given within one hour (if fluoroquinolone or vancomycin, two hours), prior to the surgical incision (or start of procedure when no incision is required)	AMA-PCPI/NCQA Contact Information cpe@ama-assn.org www.ncqa.org		Proceduralists/Surgery
PQRI 21 NQF 0268	Title: Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second Generation Cephalosporin Description: Percentage of surgical patients aged 18 years and older undergoing procedures with the indications for a first OR second generation cephalosporin prophylactic antibiotic, who had an order for cefazolin OR cefuroxime for antimicrobial prophylaxis	AMA-PCPI/NCQA Contact Information: cpe@ama-assn.org www.ncqa.org		Proceduralists/Surgery
PQRI 22 NQF 0271	Title: Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures) Description: Percentage of non-cardiac surgical patients aged 18 years and older undergoing procedures with the indications for prophylactic antibiotics AND who received a prophylactic antibiotic, who have an order for discontinuation of prophylactic antibiotics within 24 hours of surgical end time	AMA-PCPI/NCQA Contact Information: cpe@ama-assn.org www.ncqa.org		Proceduralists/Surgery
PQRI 23 NQF 0239	Title: Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) Description: Percentage of patients aged 18 years and older undergoing procedures for which VTE prophylaxis is indicated in all patients, who had an order for Low Molecular Weight Heparin (LMWH), Low-Dose Unfractionated Heparin (LDUH), adjusted- dose warfarin, fondaparinux or mechanical prophylaxis to be given within 24 hours prior to incision time or within 24 hours after surgery end time	AMA-PCPI/NCQA Contact Information: cpe@ama-assn.org www.ncqa.org		Proceduralists/Surgery
PQRI 33 NQF 0241	Title: Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge Description: Percentage of patients aged 18 years and older with a diagnosis of ischemic stroke or transient ischemic attack (TIA) with documented permanent, persistent, or paroxysmal atrial fibrillation who were prescribed an anticoagulant at discharge	AMA-PCPI/NCQA Contact Information: cpe@ama-assn.org www.ncqa.org		Neurology

Measure Number	Clinical Quality Measure Title & Description	Clinical Quality Measure Developer & Contact Information	Electronic Measure Specifications Information	Core/Specialty Measure Group
PQRI 52 NQF 0102	Title: Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy Description: Percentage of patients aged 18 years and older with a diagnosis of COPD and who have an FEV1/FVC less than 70% and have symptoms who were prescribed an inhaled bronchodilator	AMA-PCPI Contact Information: cpe@ama-assn.org		Pulmonology
PQRI 53 NQF 0047	Title: Asthma: Pharmacologic Therapy Description: Percentage of patients aged 5 through 40 years with a diagnosis of mild, moderate, or severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid) or an acceptable alternative treatment	AMA-PCPI Contact Information: cpe@ama-assn.org		Pulmonology
PQRI 65 NQF 0069	Title: Treatment for Children with Upper Respiratory Infection (URI): Avoidance of Inappropriate Use Description: Percentage of children aged 3 months through 18 years with a diagnosis of URI who were not prescribed or dispensed an antibiotic prescription on or within 3 days of the initial date of service	NCQA Contact Information: www.ncqa.org		Primary Care
PQRI 66 NQF 0002	Title: Appropriate Testing for Children with Pharyngitis Description: Percentage of children aged 2 through 18 years with a diagnosis of pharyngitis, who were prescribed an antibiotic and who received a group A streptococcus (strep) test for the episode	NCQA Contact Information: www.ncqa.org		Pediatrics, Primary Care
PQRI 71 NQF 0387	Title: Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer Description: Percentage of female patients aged 18 years and older with Stage IC through IIIC, ER or PR positive breast cancer who were prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month reporting period	AMA-PCPI/American Society of Clinical Oncology (ASCO)- National Comprehensive Cancer Network (NCCN): Contact Information: cpe@ama-assn.org http://www.asco.org/		Oncology
PQRI 72 NQF 0385	Title: Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients Description: Percentage of patients aged 18 years and older with Stage IIIA through IIIC colon cancer who are referred for adjuvant, prescribed adjuvant chemotherapy, or have previously received adjuvant chemotherapy within the 12-month reporting period	AMA-PCPI/ASCO-NCCN Contact Information: cpe@ama-assn.org http://www.asco.org/		Oncology

Measure Number	Clinical Quality Measure Title & Description	Clinical Quality Measure Developer & Contact Information	Electronic Measure Specifications Information	Core/Specialty Measure Group
PQRI 81	Title: End Stage Renal Disease (ESRD): Plan of Care for Inadequate Hemodialysis in ESRD Patients	AMA-PCPI Contact Information:		Nephrology
NQF 0323	Description: Percentage of calendar months during the 12-month reporting period in which patients aged 18 years and older with a diagnosis of ESRD receiving hemodialysis have a Kt/V ≥ 1.2 OR patients who have a Kt/V < 1.2 with a documented plan of care for inadequate hemodialysis	cpe@ama-assn.org		
PQRI 82	Title: End Stage Renal Disease (ESRD): Plan of Care for Inadequate Peritoneal Dialysis	AMA-PCPI Contact Information:		Nephrology
NQF 0321	Description: Percentage of patients aged 18 years and older with a diagnosis of ESRD receiving peritoneal dialysis who have a $Kt/V \ge 1.7$ OR patients who have a $Kt/V < 1.7$ with a documented plan of care for inadequate peritoneal dialysis at least three times (every 4 months) during the 12-month reporting period	cpe@ama-assn.org		
PQRI 86	Title: Hepatitis C: Antiviral Treatment Prescribed Description: Percentage of patients aged 18 years and older with	AMA-PCPI Contact Information:		Gastroenterology
NQF 0397	a diagnosis of chronic hepatitis C who were prescribed peginterferon and ribavirin therapy within the 12-month reporting period	cpe@ama-assn.org		
PQRI 89	Title: Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	AMA-PCPI		Gastroenterology
NQF 0401	Description: Percentage of patients aged 18 years and older with a diagnosis of hepatitis C who were counseled about the risks of alcohol use at least once within the 12-month reporting period	Contact Information: cpe@ama-assn.org		
PQRI 102	Title: Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low-Risk Prostate Cancer Patients	AMA-PCPI		Oncology
NQF 0389	Description: Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer	Contact Information: cpe@ama-assn.org		

Measure Number	Clinical Quality Measure Title & Description	Clinical Quality Measure Developer & Contact Information	Electronic Measure Specifications Information	Core/Specialty Measure Group
PQRI 106 NQF 0103	Title: Major Depressive Disorder (MDD): Diagnostic Evaluation Description: Percentage of patients aged 18 years and older with a new diagnosis or recurrent episode of MDD who met the DSM-IV criteria during the visit in which the new diagnosis or recurrent episode was identified during the measurement period	AMA-PCPI Contact Information: cpe@ama-assn.org	XIIOI IIIALIOII	Psychiatry
PQRI 107 NQF 0104	Title: Major Depressive Disorder (MDD): Suicide Risk Assessment Description: Percentage of patients aged 18 years and older with a new diagnosis or recurrent episode of MDD who had a suicide risk assessment completed at each visit during the measurement period	AMA-PCPI Contact Information: cpe@ama-assn.org		Psychiatry
PQRI 114 NQF 0028	Title: Preventive Care and Screening: Inquiry Regarding Tobacco Use Description: Percentage of patients aged 18 years or older who were queried about tobacco use one or more times within 24 months	AMA-PCPI Contact Information: cpe@ama-assn.org		Core, Pulmonology, Primary Care
PQRI 115 NQF 0027	Title: Preventive Care and Screening: Advising Smokers to Quit Description: Percentage of patients aged 18 years and older and are smokers who received advice to quit smoking	NCQA Contact Information: www.ncqa.org		Pulmonology, Primary Care
PQRI 117 NQF 0055	Title: Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient Description: Percentage of patients aged 18 through 75 years with a diagnosis of diabetes mellitus who had a dilated eye exam	AMA-PCPI Contact Information: cpe@ama-assn.org		Endocrinology
PQRI 118 NQF 0066	Title: Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Patients with CAD and Diabetes and/or Left Ventricular Systolic Dysfunction (LVSD) Description: Percentage of patients aged 18 years and older with a diagnosis of CAD who also have diabetes mellitus and/or LVSD (LVEF < 40%) who were prescribed ACE inhibitor or ARB therapy	AMA-PCPI Contact Information: cpe@ama-assn.org		Cardiology

Measure Number	Clinical Quality Measure Title & Description	Clinical Quality Measure Developer & Contact Information	Electronic Measure Specifications Information	Core/Specialty Measure Group
PQRI 119 TO NQF 0062	Title: Diabetes Mellitus: Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients Description: Percentage of patients aged 18 through 75 years with diabetes mellitus who received urine protein screening or medical attention for nephropathy during at least one office visit within 12 months	NCQA Contact Information: www.ncqa.org	Intornation	Endocrinology
PQRI 121 Ambulatory Quality Alliance (AQA) adopted	Title: Chronic Kidney Disease (CKD): Laboratory Testing (Calcium, Phosphorus, Intact Parathyroid Hormone (iPTH) and Lipid Profile) Description: Percentage of patients aged 18 years and older with a diagnosis of advanced CKD (stage 4 or 5, not receiving Renal Replacement Therapy [RRT]), who had the following laboratory testing ordered within 12 months: serum levels of calcium, phosphorus and intact PTH, and lipid profile	AMA-PCPI Contact Information: cpe@ama-assn.org		Nephrology
PQRI 122 AQA adopted	Title: Chronic Kidney Disease (CKD): Blood Pressure Management Description: Percentage of patient visits for patients aged 18 years and older with a diagnosis of advanced CKD (stage 4 or 5, not receiving Renal Replacement Therapy [RRT]), with a blood pressure < 130/80 mmHg OR blood pressure ≥ 130/80 mmHg with a documented plan of care	AMA-PCPI Contact Information: cpe@ama-assn.org		Nephrology
PQRI 123 AQA adopted	Title: Chronic Kidney Disease (CKD): Plan of Care – Elevated Hemoglobin for Patients Receiving Erythropoiesis-Stimulating Agents (ESA) Description: Percentage of calendar months during the 12-month reporting period in which patients aged 18 years and older with a diagnosis of advanced CKD (stage 4 or 5, not receiving Renal Replacement Therapy [RRT]), receiving ESA therapy, have a hemoglobin < 13 g/dL OR patients whose hemoglobin is ≥ 13 g/dL and have a documented plan of care	AMA-PCPI Contact Information: cpe@ama-assn.org		Nephrology
PQRI 127 NQF 0416	Title: Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention — Evaluation of Footwear Description: Percentage of patients aged 18 years and older with a diagnosis of diabetes mellitus who were evaluated for proper footwear and sizing	American Podiatric Medical Association (APMA) Contact Information: http://www.apma.org/		Podiatry

Measure Number	Clinical Quality Measure Title & Description	Clinical Quality Measure Developer & Contact Information	Electronic Measure Specifications	Core/Specialty
PQRI 128 NQF 0421	Title: Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Description: Percentage of patients aged 18 years and older with a calculated BMI in the past six months or during the current visit documented in the medical record AND if the most recent BMI is outside parameters, a follow-up plan is documented Parameters: Age 65 and older BMI ≥30 or <22 Age 18 - 64 BMI ≥25 or <18.5	CMS/Quality Insights of Pennsylvania (QIP) Contact Information: PORI inquiry@cms.hhs.go V	Information	Measure Group Cardiology, Endocrinology, Primary Care, Obstetrics and Gynecology
PQRI 145 NQF 0510	Title: Radiology: Exposure Time Reported for Procedures Using Fluoroscopy Description: Percentage of final reports for procedures using fluoroscopy that include documentation of radiation exposure or exposure time	AMA-PCPI/NCQA Contact Information: cpe@ama-assn.org www.ncqa.org		Radiology
PQRI 146 NQF 0508	Title: Radiology: Inappropriate Use of "Probably Benign" Assessment Category in Mammography Screening Description: Percentage of final reports for screening mammograms that are classified as "probably benign"	AMA-PCPI/NCQA Contact Information: cpe@ama-assn.org www.ncqa.org		Radiology
PQRI 147 NQF 0511	Title: Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy Description: Percentage of final reports for all patients. regardless of age, undergoing bone scintigraphy that include physician documentation of correlation with existing relevant imaging studies (e.g., x-ray, MRI, CT, etc.) that were performed	AMA-PCPI Contact Information: cpe@ama-assn.org		Radiology
PQRI 153 AQA adopted	Title: Chronic Kidney Disease (CKD): Referral for Arteriovenous (AV) Fistula Description: Percentage of patients aged 18 years and older with the diagnosis of advanced CKD (stage 4 or 5, not receiving Renal Replacement Therapy [RRT]), who were referred for AV fistula at least once during the 12-month reporting period	AMA-PCPI Contact Information: cpe@ama-assn.org		Nephrology
PQRI 163 NQF 0056	Title: Diabetes Mellitus: Foot Exam Description: The percentage of patients aged 18 through 75 years with diabetes who had a foot examination	NCQA Contact Information: www.ncqa.org		Podiatry

Measure Number	Clinical Quality Measure Title & Description	Clinical Quality Measure Developer & Contact Information	Electronic Measure Specifications Information	Core/Specialty Measure Group
PQRI 183 NQF 0399	Title: Hepatitis C: Hepatitis A Vaccination in Patients with HCV Description: Percentage of patients aged 18 years and older with a diagnosis of hepatitis C who received at least one injection of hepatitis A vaccine, or who have documented immunity to hepatitis A	AMA-PCPI Contact Information: cpe@ama-assn.org		Gastroenterology
PQRI 184 NQF 0400	Title: Hepatitis C: Hepatitis B Vaccination in Patients with HCV Description: Percentage of patients aged 18 years and older with a diagnosis of hepatitis C who received at least one injection of hepatitis B vaccine, or who have documented immunity to hepatitis B	AMA-PCPI Contact Information: cpe@ama-assn.org		Gastroenterology
PQRI 185 AQA adopted	Title: Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use Description: Percentage of patients aged 18 years and older receiving a surveillance colonoscopy and a history of colonic polyp(s) in a previous colonoscopy, who had a follow-up interval of 3 or more years since their last colonoscopy documented in the colonoscopy report	AMA-PCPI/NCQA Contact Information: cpe@ama-assn.org www.ncqa.org		Gastroenterology
PQRI 195 NQF 0507	Title: Stenosis Measurement in Carotid Imaging Reports Description: Percentage of final reports for carotid imaging studies (neck MR angiography [MRA], neck CT angiography [CTA], neck duplex ultrasound, carotid angiogram) performed for patients aged 18 years and older with the diagnosis of ischemic stroke or transient ischemic attack (TIA) that include direct or indirect reference to measurements of distal internal carotid diameter as the denominator for stenosis measurement	AMA-PCPI/NCQA Contact Information: cpe@ama-assn.org www.ncqa.org		Radiology
PQRI 197 NQF 0074	Title: Coronary Artery Disease (CAD): Drug Therapy for Lowering LDL-Cholesterol Description: Percentage of patients aged 18 years and older with a diagnosis of CAD who were prescribed a lipid-lowering therapy (based on current ACC/AHA guidelines)	AMA-PCPI Contact Information: cpe@ama-assn.org		Cardiology, Primary Care
PQRI 200 NQF 0084	Title: Heart Failure: Warfarin Therapy for Patients with Atrial Fibrillation Description: Percentage of all patients aged 18 and older with a diagnosis of heart failure and paroxysmal or chronic atrial fibrillation who were prescribed warfarin therapy	AMA-PCPI Contact Information: cpe@ama-assn.org		Cardiology

Measure Number	Clinical Quality Measure Title & Description	Clinical Quality Measure Developer & Contact Information	Electronic Measure Specifications Information	Core/Specialty Measure Group
PQRI 201 NQF 0073	Title: Ischemic Vascular Disease (IVD): Blood Pressure Management Control Description: Percentage of patients aged 18 years and older with Ischemic Vascular Disease (IVD) who had most recent blood pressure in control (less than 140/90 mmHg)	NCQA Contact Information: www.ncqa.org		Neurology
PQRI 202 NQF 0075	Title: Ischemic Vascular Disease (IVD): Complete Lipid Profile Description: Percentage of patients aged 18 years and older with Ischemic Vascular Disease (IVD) who received at least one lipid profile within 12 months	NCQA Contact Information: www.ncqa.org		Primary Care, Neurology
PQRI 203 NQF 0075	Title: Ischemic Vascular Disease (IVD): Low Density Lipoprotein (LDL-C) Control Description: Percentage of patients aged 18 years and older with Ischemic Vascular Disease (IVD) who had most recent LDL-C level in control (less than 100 mg/dl)	NCQA Contact Information: www.ncqa.org		Primary Care, Neurology
PQRI 204 NQF 0068	Title: Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic Description: Percentage of patients aged 18 years and older with Ischemic Vascular Disease (IVD) with documented use of aspirin or other antithrombotic	NCQA Contact Information: www.ncqa.org		Cardiology, Endocrinology, Primary Care, Neurology
NQF 0001	Title: Asthma assessment Description: Percentage of patients who were evaluated during at least one office visit for the frequency (numeric) of daytime and nocturnal asthma symptoms	AMA-PCPI Contact Information: www.ama-assn.org		Pulmonology, Prima Care
NQF 0004	Title: Initiation and Engagement of Alcohol and Other Drug Dependence Treatment: (a) Initiation, (b) Engagement Description: Percentage of adults aged 18 and over diagnosed with AOD abuse or dependence and receiving a related service who initiate treatment Assessment of the degree to which members engage in treatment with two additional AOD treatments within 30 days after initiating treatment.	NCQA Contact Information: www.ncqa.org		Primary Care, Psychiatry
NQF 0012	Title: Prenatal Screening for Human Immunodeficiency Virus (HIV) Description: Percentage of patients who gave birth during a 12-month period who were screened for HIV infection during the first or second prenatal care visit	AMA-PCPI Contact Information: www.ama-assn.org		Obstetrics and Gynecology

Measure Number	Clinical Quality Measure Title & Description	Clinical Quality Measure Developer & Contact Information	Electronic Measure Specifications Information	Core/Specialty Measure Group
NQF 0013	Title: Blood pressure measurement Description: Percentage of patient visits with blood pressure measurement recorded among all patient visits for patients aged > 18 years with diagnosed hypertension.	AMA-PCPI Contact Information: www.ama-assn.org		Core
NQF 0014	Title: Prenatal Anti-D Immune Globulin Description: Percentage of D-negative, unsensitized patients who gave birth during a 12-month period who received anti-D immune globulin at 26-30 weeks gestation	AMA-PCPI Contact Information: www.ama-assn.org		Obstetrics and Gynecology
NQF 0018	Title: Controlling High Blood Pressure Description: Percentage of patients with last BP < 140/80 mm Hg.	NCQA Contact Information: www.ncqa.org		Primary Care
NQF 0022	Title: Drugs to be avoided in the elderly: a. Patients who receive at least one drug to be avoided, b. Patients who receive at least two different drugs to be avoided. Description: Percentage of patients ages 65 years and older who received at least one drug to be avoided in the elderly in the measurement year. Percentage of patients 65 years of age and older who received at least two different drugs to be avoided in the elderly in the measurement year.	NCQA Contact Information: www.ncqa.org	•	Core
NQF 0024	Title: Body Mass Index (BMI) 2 through 18 years of age Description: Percentage children, 2 through 18 years of age, whose weight is classified based on BMI percentile for age and gender	National Initiative for Children's Healthcare Quality Contact Information: http://www.nichq.org/		Pediatrics, Primary Care
NQF 0026	Title: Measure pair - a. Tobacco use prevention for infants, children and adolescents, b. Tobacco use cessation for infants, children and adolescents Description: Percentage of patients' charts showing either that there is no tobacco use/exposure or (if a user) that the current use was documented at the most recent clinic visit. Percentage of patients with documented tobacco use or exposure at the latest visit who also have documentation that their cessation interest was assessed or that they received advice to quit.	Institute for Clinical Systems Improvement (ICSI) Contact Information: http://www.icsi.org/		Pediatrics

Measure Number	Clinical Quality Measure Title & Description	Clinical Quality Measure Developer & Contact Information	Electronic Measure Specifications Information	Core/Specialty Measure Group
NQF 0032	Title: Cervical Cancer Screening Description: Percentage of women 18-64 years of age, who received one or more Pap tests during the measurement year or the 2 years prior to the measurement year.	NCQA Contact Information: www.ncqa.org		Oncology, Primary Care, Obstetrics and Gynecology
NQF 0033	Title: Chlamydia screening in women Description: Percentage of eligible women who were identified as sexually active who had at least one test for chlamydia during the measurement year.	NCQA Contact Information: www.ncqa.org		Obstetrics and Gynecology
NQF 0036	Title: Use of appropriate medications for people with asthma Description: Percentage of patients who were identified as having persistent asthma during the measurement year and the year prior to the measurement year and who were dispensed a prescription for either an inhaled corticosteroid or acceptable alternative medication during the measurement year.	NCQA Contact Information: www.ncqa.org		Pulmonology, Primary Care
NQF 0038	Title: Childhood Immunization Status Description: Percentage of children 2 years of age who had four DtaP/DT, three IPV, one MMR, three H influenza type B, three hepatitis B, one chicken pox vaccine (VZV) and four pneumococcal conjugate vaccines by their second birthday. The measure calculates a rate for each vaccine and two separate combination rates.	NCQA Contact Information: www.ncqa.org		Primary Care, Pediatrics
NQF 0052	Title: Low back pain: use of imaging studies Description: Percentage of patients with new low back pain who received an imaging study (plain x-ray, MRI, CT scan) conducted on the episode start date or in the 28 days following the episode start date.	NCQA Contact Information: www.ncqa.org		Primary Care, Radiology
NQF 0060	Title: Hemoglobin A1c test for pediatric patients Description: Percentage of pediatric patients with diabetes with a HBA1c test in a 12-month measurement period.	NCQA Contact Information: www.ncqa.org		Endocrinology, Pediatrics, Primary Care

Measure Number	Clinical Quality Measure Title & Description	Clinical Quality Measure Developer & Contact Information	Electronic Measure Specifications Information	Core/Specialty Measure Group
NQF 0105	Title: New Episode of Depression: (a) Optimal Practitioner Contacts for Medication Management, (b) Effective Acute Phase Treatment,(c)Effective Continuation Phase Treatment Description: Percentage of patients who were diagnosed with a new episode of depression and treated with antidepressant medication, and who had at least three follow-up contacts with a practitioner during the 84-day (12-week) Acute Treatment	NCQA Contact Information: www.ncqa.org		Psychiatry, Primary Care
	Phase b. Percentage of patients who were diagnosed with a new episode of depression, were treated with antidepressant medication and remained on an antidepressant drug during the entire 84-day Acute Treatment Phase c. Percentage of patients who were diagnosed with a new episode of depression and treated with antidepressant medication and who remained on an antidepressant drug for at least 180			,
NQF 0106	days. Title: Diagnosis of attention deficit hyperactivity disorder (ADHD) in primary care for school age children and adolescents Description: Percentage of patients newly diagnosed with attention deficit hyperactivity disorder (ADHD) whose medical record contains documentation of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) or Diagnostic and Statistical Manual for Primary Care (DSM-PC) criteria being addressed.	ICSI Contact Information: http://www.icsi.org/		Pediatrics, Primary Care
NQF 0107	Title: Management of attention deficit hyperactivity disorder (ADHD) in primary care for school age children and adolescents Description: Percentage of patients diagnosed with attention deficit hyperactivity disorder (ADHD) and on first-line medication whose medical record contains documentation of a follow-up visit twice a year.	ICSI Contact Information: http://www.icsi.org/		Pediatrics, Primary Care

Measure Number	Clinical Quality Measure Title & Description	Clinical Quality Measure Developer & Contact Information	Electronic Measure Specifications Information	Core/Specialty Measure Group
NQF 0108	Title: ADHD: Follow-Up Care for Children Prescribed	NCQA		Pediatrics, Primary
	Attention-Deficit/Hyperactivity Disorder (ADHD) Medication.	Contact Information:		Care
	Description: a. Initiation Phase: Percentage of children 6 – 12	www.ncqa.org		
	years of age as of the Index Prescription Episode Start Date with			
	an ambulatory prescription dispensed for and ADHD medication		i i	
	and who had one follow-up visit with a practitioner with		•	
	prescribing authority during the 30-Day Initiation			
	Phase b. Continuation and Maintenance (C&M) Phase:	·		
	Percentage of children 6 – 12 years of age as of the Index			
	Prescription Episode Start Date with an ambulatory prescription			
	dispensed for ADHD medication who remained on the			
	medication for at least 210 days and who in addition to the visit			
,	in the Initiation Phase had at least two additional follow-up visits			
	with a practitioner within 270 days (9 months) after the Initiation Phase ends.			
NQF 0110	Title: Bipolar Disorder and Major Depression: Appraisal for	Center for Quality Assessment		Psychiatry, Primary
	alcohol or chemical substance use	and Improvement in Mental		Care
	Description: Percentage of patients with depression or bipolar	Health		Cuit
	disorder with evidence of an initial assessment that includes an	Contact Information:		
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	appraisal for alcohol or chemical substance use	http://www.cqaimh.org/	·	
NQF 0299	Title: Surgical Site Infection Rate	Centers for Disease Control		Proceduralists/Surgery
	Description: Percentage of surgical site infections occurring	and Prevention (CDC)		
	within thirty days after the operative procedure if no implant is left in place or with one year if an implant is in place in patients	Contact Information:		
	who had an NHSN operative procedure performed during a	http://www.cdc.gov/		
	specified time period and the infection appears to be related to			
	the operative procedure.			

Measure Number	Clinical Quality Measure Title & Description	Clinical Quality Measure Developer & Contact Information	Electronic Measure Specifications Information	Core/Specialty Measure Group
NQF 0471	Title: Cesarean Rate for low-risk first birth women (aka NTSV CS rate) Description: Percentage of low-risk first birth women (aka NTSV CS rate: nulliparous, term, singleton, vertex) with a Cesarean rate that has the most variation among practicioners, hospitals, regions and states. Unlike other cesarean measures, it	California Maternal Quality Care Collaborative (CMQCC) Contact Information: http://cmqcc.org/	··	Obstetrics and Gynecology
	focuses attention on the proportion of cesarean births that is affected by elective medical practices such as induction and early labor admission. Furthermore, the success (or lack thereof) of management of the first labor directly impacts the remainder of the woman's reproductive life (especially given the current high rate of repeat cesarean births).			
NQF 0513	Title: Use of Contrast: Thorax CT Description: Thorax CT – Use of combined studies (with and without contrast)	CMS Contact Information: http://www.cms.hhs.gov/	:	Radiology
NQF 0519	Title: Diabetic Foot Care and Patient Education Implemented Description: Percent of diabetic patients for whom physician-ordered monitoring for the presence of skin lesions on the lower extremities and patient education on proper foot care were implemented during their episode of care	CMS Contact Information: http://www.cms.hhs.gov/		Podiatry
NQF EC-013-08	Title: Comprehensive Diabetes Care: HbA1c Control (<8.0%) Description: The percentage of members 18-75 years of age with diabetes (Type 1 and Type 2) who had HbA1c control (<8.0%).	NCQA Contact Information: www.ncqa.org	·	Endocrinology, Primary Care
Not applicable	Title: Hysterectomy rates Description:			Obstetrics and Gynecology
Not applicable	Title: Appropriate antibiotic use for ear infections Description:			Pediatrics, Primary Care
Not applicable	Title: Statin after Myocardial Infarction Description:			Cardiology
Not Applicable	Title: 30 day Readmission Rate Description:			Proceduralists/Surgery
Not Applicable	Title: 30 Readmission Rate following deliveries Description:			Obstetrics and Gynecology
Not Applicable	Title: Use of CT scans Description: Number of repeat CT scans within 60 days			Pulmonology

convey the clinical quality measure's title, number, owner/developer and contact information, and a link to existing electronic specifications where applicable.

TABLE 20: Proposed Clinical Quality Measures for Electronic Submission by Eligible Hospitals for Payment Year 2011-2012

Measure		Electronic Measure
Number		Specifications
Identifier	Measure Title, Description & Measure Developer	Information
ED-1	Title: Emergency Department Throughput – admitted patients	http://www.hitsp.org/
	Median time from ED arrival to ED departure for admitted	ConstructSet_Details.a
NQF 0495	patients	spx?&PrefixAlpha=5
•	Description: Median time from emergency department arrival to	&PrefixNumeric=906
	time of departure from the emergency room for patients admitted	
	to the facility from the emergency department	
	Measure Developer: CMS/Oklahoma Foundation for Medical	
	Quality (OFMQC)	
ED-2	Title: Emergency Department Throughput – admitted patients	http://www.hitsp.org/
	Admission decision time to ED departure time for admitted	ConstructSet_Details.a
NQF 0497	patients	spx?&PrefixAlpha=5
	Description: Median time from admit decision time to time of	&PrefixNumeric=906
	departure from the emergency department of emergency	
	department patients admitted to inpatient status	
	Measure Developer: CMS/OFMQ	
ED-3	Title: Emergency Department Throughput – discharged patients	
	Median Time from ED Arrival to ED Departure for Discharged	
NQF 0496	ED Patients	
	Description: Median Time from ED arrival to time of departure	
	from the ED for patients discharged from the ED	
	Measure Developer: CMS/OFMQ	
Stroke-2	Title: Ischemic stroke – Discharge on anti-thrombotics	http://www.hitsp.org/
-	Description: Ischemic stroke patients prescribed antithrombotic	ConstructSet_Details.a
NQF 0435	therapy at hospital discharge	spx?&PrefixAlpha=5
	Measure Developer: The Joint Commission	&PrefixNumeric=906
Stroke-3	Title: Ischemic stroke – Anticoagulation for A-fib/flutter	http://www.hitsp.org/
	Description: Ischemic stroke patients with atrial	ConstructSet_Details.a
NQF 0436	fibrillation/flutter who are prescribed anticoagulation therapy at	spx?&PrefixAlpha=5
	hospital discharge.	&PrefixNumeric=906
	Measure Developer: The Joint Commission	

Measure Number		Electronic Measure Specifications
Identifier	Measure Title, Description & Measure Developer	Information
Stroke-4	Title: Ischemic stroke - Thrombolytic therapy for patients	http://www.hitsp.org/
Noroton	arriving within 2 hours of symptom onset	ConstructSet_Details.a
NQF 0437	Description: Acute ischemic stroke patients who arrive at this	spx?&PrefixAlpha=5
	hospital within 2 hours of time last known well and for whom IV	&PrefixNumeric=906
	t-PA was initiated at this hospital within 3 hours of time last	
	known well.	
Causales 5	Measure Developer: The Joint Commission	
Stroke-5	Title: Ischemic or hemorrhagic stroke – Antithrombotic therapy	http://www.hitsp.org/
NOE 0420	by day 2	ConstructSet_Details.a
NQF 0438	Description: Ischemic stroke patients administered	spx?&Prefix Alpha=5
	antithrombotic therapy by the end of hospital day 2.	&PrefixNumeric=906
0. 1. 6	Measure Developer: The Joint Commission	
Stroke-6	Title: Ischemic stroke – Discharge on statins	http://www.hitsp.org/
NOFAR	Description: Ischemic stroke patients with LDL > 100 mg/dL, or	ConstructSet_Details.a
NQF 0439	LDL not measured, or, who were on a lipid-lowering medication	spx?&Prefix Alpha=5
	prior to hospital arrival are prescribed statin medication at	&PrefixNumeric=906
•	hospital discharge.	
0. 1 0	Measure Developer: The Joint Commission	
Stroke-8	Title: Ischemic or hemorrhagic stroke – Stroke education	http://www.hitsp.org/
NOT 0440	Description: Ischemic or hemorrhagic stroke patients or their	ConstructSet_Details.a
NQF 0440	caregivers who were given educational materials during the	spx?&PrefixAlpha=5
	hospital stay addressing all of the following: activation of	&PrefixNumeric=906
	emergency medical system, need for follow-up after discharge,	
	medications prescribed at discharge, risk factors for stroke, and	
	warning signs and symptoms of stroke.	
Stroke-10	Measure Developer: The Joint Commission Title: Ischemic or hemorrhagic stroke – Rehabilitation	h44//
DILUKU-1U	assessment	http://www.hitsp.org/
NQF 0441	Description: Ischemic or hemorrhagic stroke patients who were	ConstructSet_Details.a
71/51 0441	assessed for rehabilitation services.	spx?&PrefixAlpha=5 &PrefixNumeric=906
	Measure Developer: The Joint Commission	&PrefixIvumeric=906
VTE-1	Title: VTE prophylaxis within 24 hours of arrival	hetmal/marries hitemany
- X 13-1	Description: This measure assesses the number of patients who	http://www.hitsp.org/
NQF 0371	received VTE prophylaxis or have documentation why no VTE	ConstructSet_Details.a
11/21 02/1	prophylaxis was given the day of or the day after hospital	spx?&PrefixAlpha=5
	admission or surgery end date for surgeries that start the day of or	&PrefixNumeric=906
	the day after hospital admission.	ŀ
	Measure Developer: The Joint Commission	
	Micasure Developer. The John Commission	i

Measure		Electronic Measure
Number		Specifications
Identifier	Measure Title, Description & Measure Developer	Information
VTE-2	Title: ICU VTE prophylaxis	http://www.hitsp.org/
	Description: This measure assesses the number of patients who	ConstructSet_Details.a
NQF 0372	received VTE prophylaxis or have documentation why no VTE	spx?&PrefixAlpha=5
	prophylaxis was given the day of or the day after the initial	&PrefixNumeric=906
	admission (or transfer) to the Intensive Care Unit (ICU) or	
	surgery end date for surgeries that start the day of or the day after	
	ICU admission (or transfer).	
	Measure Developer: The Joint Commission	
VTE-3	Title: Anticoagulation overlap therapy	http://www.hitsp.org/
	Description: This measure assesses the number of patients	ConstructSet Details.a
NQF 0373	diagnosed with confirmed VTE who received an overlap of	spx?&PrefixAlpha=5
	parenteral (intravenous [IV] or subcutaneous [subcu])	&PrefixNumeric=906
	anticoagulation and warfarin therapy. For patients who received	
	less than five days of overlap therapy, they must be discharged on	
	both medications. Overlap therapy must be administered for at	
	least five days with an international normalized ratio (INR) ≥ 2	
	prior to discontinuation of the parenteral anticoagulation therapy	
	or the patient must be discharged on both medications.	
	Measure Developer: The Joint Commission	
VTE-4	Title: Platelet monitoring on unfractionated heparin	http://www.hitsp.org/
	Description: This measure assesses the number of patients	ConstructSet_Details.a
NQF 0374	diagnosed with confirmed VTE who received intravenous (IV)	spx?&PrefixAlpha=5
	UFH therapy dosages AND had their platelet counts monitored	&PrefixNumeric=906
	using defined parameters such as a nomogram or protocol.	
	Measure Developer: The Joint Commission	
VTE-5	Title: VTE discharge instructions	http://www.hitsp.org/
37050055	Description: This measure assesses the number of patients	ConstructSet_Details.a
NQF 0375	diagnosed with confirmed VTE that are discharged to home, to	spx?&PrefixAlpha=5
	home with home health, home hospice or discharged/transferred	&PrefixNumeric=906
	to court/law enforcement on warfarin with written discharge	
	instructions that address all four criteria: compliance issues,	
	dietary advice, follow-up monitoring, and information about the	
	potential for adverse drug reactions/interactions.	
Name (Measure Developer: The Joint Commission	
VTE-6	Title: Incidence of potentially preventable VTE	http://www.hitsp.org/
NOT 027	Description: This measure assesses the number of patients	ConstructSet Details.a
NQF 0376	diagnosed with confirmed VTE during hospitalization (not	spx?&PrefixAlpha=5
	present on arrival) who did not receive VTE prophylaxis between	&PrefixNumeric=906
	hospital admission and the day before the VTE diagnostic testing	
	order date.	
	Measure Developer: The Joint Commission	

Measure		Electronic Measure
Number	Marguer Title Description & Marguer Developer	Specifications Information
Identifier	Measure Title, Description & Measure Developer	Intormation
RHQDAPU	Title: Primary PCI Received Within 90 Minutes of Hospital	
AMI-8a	Arrival	
NOTION	Description: Acute myocardial infarction (AMI) patients with	
NQF 0163	ST-segment elevation or	
	LBBB on the ECG closest to arrival time receiving primary PCI during the hospital stay	
•	with a time from hospital arrival to PCI of 90 minutes or less	
	Measure Developer: CMS/OFMQ	
RHQDAPU	Title: Blood Cultures Performed in the Emergency Department	
PN-3b	Prior to Initial Antibiotic Received in Hospital	
11, 50	Description: Pneumonia patients whose initial emergency room	
NQF 0148	blood culture specimen was collected prior to first hospital dose	
110110	of antibiotics. This measure focuses on the treatment provided to	
	Emergency Department patients prior to admission orders.	
	Measure Developer: CMS/OFMQ	
RHQDAPU	Title: Aspirin Prescribed at Discharge	
AMI-2	Description: Acute myocardial infarction (AMI) patients who	
	are prescribed aspirin at hospital discharge	
NQF 0142	Measure Developer: CMS/OFMQ	
RHQDAPU	Title: Angiotensin Converting Enzyme Inhibitor(ACEI) or	
AMI-3	Angiotensin Receptor Blocker (ARB) for Left Ventricular	
	Systolic	
NQF 0137	Dysfunction (LVSD)	
	Description: Acute myocardial infarction (AMI) patients with	
	left ventricular systolic dysfunction (LVSD) who are prescribed	
	an ACEI or ARB at hospital discharge. For purposes of this	
	measure, LVSD is defined as chart documentation of a left	
	ventricular ejection fraction (LVEF) less than 40% or a narrative	
	description of left ventricular systolic (LVS) function consistent	
	with moderate or severe systolic dysfunction.	
	Measure Developer: CMS/OFMQ	
RHQDAPU	Title: Beta-Blocker Prescribed at Discharge	· .
AMI-5	Description: Acute myocardial infarction (AMI) patients who	
NOTALO	are prescribed a betablocker at hospital discharge	
NQF 0160	Measure Developer: CMS/OFMQ	
RHQDAPU	Title & Description: Hospital Specific 30 day Risk-Standardized	
AMI-READ	Readmission Rate following AMI admission	
NOT OFF	Measure Developer: CMS	
NQF 0505	Tidle Henrical Consider 20 Jan Dete following AMI admin-	
Not applicable	Title: Hospital Specific 30 day Rate following AMI admission	<u> </u>

Measure Number		Electronic Measure Specifications
Identifier	Measure Title, Description & Measure Developer	Information
RHQDAPU	Title & Description: Hospital Specific 30 day Risk-Standardized	
HF-READ	Readmission Rate following Heart Failure admission Measure Developer: CMS/OFMQ	
NQF 0330		
Not applicable	Title: Hospital Specific 30 day Rate following Heart Failure admission	
RHQDAPU PNE-READ	Title & Description: Hospital Specific 30 day Risk-Standardized Readmission Rate following Pneumonia admission	
	Measure Developer: CMS	
NQF 0506	Trial - Hamile Consider 20 day Date Callering December 2	
Not applicable	Title: Hospital Specific 30 day Rate following Pneumonia admission	
NQF 0528	Title: Infection SCIP Inf-2 Prophylactic antibiotics consistent with current recommendations	
	Description: Surgical patients who received prophylactic	
	antibiotics consistent with current guidelines (specific to each	
	type of surgical procedure).	
	Measure Developer: CMS/OFMQ	
NQF 0302	Title: Ventilator Bundle	· · · · · · · · · · · · · · · · · · ·
	Description: Percentage of intensive care unit patients on	
	mechanical ventilation at time of survey for whom all four	
	elements of the ventilator bundle are documented and in place.	
	The ventilator bundle elements are: •Head of bed (HOB)	
	elevation 30 degrees or greater (unless medically	
	contraindicated); noted on 2 different shifts within a 24 hour	
	period •Daily "sedation interruption" and daily assessment of	
	readiness to extubate; process includes interrupting sedation until	
	patient follow commands and patient is assessed for	
	discontinuation of mechanical ventilation; Parameters of	
	discontinuation include: resolution of reason for intubation;	
	inspired oxygen content roughly 40%; assessment of patients	
	ability to defend airway after extubation due to heavy sedation;	
	minute ventilation less than equal to 15 liters/minute; and	
	respiratory rate/tidal volume less than or equal to	
	105/min/L(RR/TV<105)•SUD (peptic ulcer disease) prophylaxis	
	DVT (deep venous thrombosis) prophylaxis	
	Measure Developer: IHI	


Measure Number Identifier	Measure Title, Description & Measure Developer	Electronic Measure Specifications Information
NQF 0298	Title: Central Line Bundle Compliance	Airoi matjon
	Description: Percentage of intensive care patients with central	{
	lines for whom all elements of the central line bundle are	
	documented and in place. The central line bundle elements	
	include: Hand hygiene, Maximal barrier precautions upon	•
	insertion •Chlorhexidine skin antisepsis •Optimal catheter site	
	selection, with subclavian vein as the preferred site for non-	
	tunneled catheters in patients 18 years and older •Daily review of	
	line necessity with prompt removal of unnecessary lines	
	Measure Developer: IHI	
NQF 0140	Title: Ventilator-associated pneumonia for ICU and high-risk	
0-10 1911	nursery (HRN) patients	
	Description: Percentage of ICU and HRN patients who over a	
	certain amount of days have ventilator-associated pneumonia	
NQF 0138	Measure Developer: CDC	
14Q1,0120	Title: Urinary catheter-associated urinary tract infection for	
	intensive care unit (ICU) patients	
	Description: Percentage of intensive care unit patients with	×
	urinary catheter-associated urinary tract infections	
NQF 0139	Measure Developer: CDC	
NQF 0139	Title: Central line catheter-associated blood stream infection rate	
	for ICU and high-risk nursery (HRN) patients	
	Description: Percentage of ICU and high-risk nursery patients,	
	who over a certain amount of days acquired a central line	
	catheter-associated blood stream infections over a specified	
	amount of line-days	
TOT 0000	Measure Developer: CDC	
NQF 0329	Title: All-Cause Readmission Index (risk adjusted)	
	Description: Overall inpatient 30-day hospital readmission rate.	
	Measure Developer: United Health Group	
Not applicable	Title: All-Cause Readmission Index	
	Description: Overall inpatient 30-day hospital readmission rate.	

TABLE 21: Proposed Alternative Medicaid Clinical Quality Measures for Medicaid Eligible Hospitals

NQF#	Measure Title, Description & Measure Developer	Electronic Measure
0341	Title: PICU Pain Assessment on Admission	Specifications Information
02.1	Description: Percentage of PICU patients receiving:	
	a. Pain assessment on admission	
	b. Periodic pain assessment.	
	Measure Developer: Vermont Oxford Network	
0348	Title: Iotrogenic pneumothorax in non-neonates (pediatric up to	<u> </u>
	17 years of age)	
•	Description: Percent of medical and surgical discharges, age	<u>'</u>
	under 18 years, with ICD-9-CM code of iatrogenic pneumothorax	
	in any secondary diagnosis field.	
	Measure Developer: AHRQ	_
0362	Title: Foreign body left after procedure, age under 18 years	
	Description: Discharges with foreign body accidentally left in	
	during procedure per 1,000 discharges	
	Measure Developer: AHRQ	
0151	Title: Pneumonia Care PNE-5c Antibiotic	
	Description: Percentage of pneumonia patients 18 years of age	·
	and older who receive their first dose of antibiotics within 6 hours	
	after arrival at the hospital	
	Measure Developer: CMS/OFMQ	
0147	Title: Pneumonia Care PN-6 Antibiotic selection	
	Description: Percentage of pneumonia patients 18 years of age or	
,	older selected for initial receipts of antibiotics for community-	
	acquired pneumonia (CAP).	
	Measure Developer: CMS/OFMQ	-
0356	Title: Pneumonia Care PN-3a Blood culture	
	Description: Percent of pneumonia patients, age 18 years or	
	older, transferred or admitted to the ICU within 24 hours of	
	hospital arrival who had blood cultures performed within 24 hours	
	prior to or 24 hours after arrival at the hospital.	
	Measure Developer: CMS/OFMQ	
0527	Title: Infection SCIP Inf-1 Prophylactic antibiotic received within	
	1 hour prior to surgical incision	
	Description: Surgical patients with prophylactic antibiotics	
	initiated within 1 hour prior to surgical incision. Patients who	
	received vancomycin or a fluoroquinolone for prophylactic	
	antibiotics should have the antibiotics initiated within 2 hours	
	prior to surgical incision. Due to the longer infusion time required	
	for vancomycin or a fluoroquinolone, it is acceptable to start these	
	antibiotics within 2 hours prior to incision time.	
	Measure Developer: CMS/OFMQ	

2010 Plan Year	- Summ	nary of	Commor	n Servic	es
Covered Benefits	ARHealth			ARHealth HD PPO	
and Services*	In-Network Copayment	In-Network Coinsurance	Out-of-Network Coinsurance	In-Network Coinsurance	Out-of-Network Coinsurance
Deductible - Individual	-	\$0	\$1,000	\$1,500	\$3,000
Deductible - Family	-	\$0	\$2,000	\$3,000	\$6,000
Annual Coinsurance Limit - Individual (after deductible)	-	\$1,500	\$5,000	\$2,500	\$5,000
Annual Coinsurance Limit - Family (after deductible)	<u>.</u>	\$3,000	\$10,000	\$5,000	\$10,000
Lifetime Maximum	-	-	\$1,000,000	-	\$1,000,000
Physician / Specialist Services					
Primary Care Physician Office Visit	\$25	0%	40%	20%	40%
Specialist Office Visit / Specialty Care Services	\$35	0%	40%	20%	40%
Other Physician Services provided under Out-Patient or In-Patient Care	\$0	20%	40%	20%	40%
Pharmacy Benefit					
Prescription - Generic - Tier I	\$10	0%	0%	20%	20%
Prescription - Preferred - Tier II	\$30	0%	0%	20%	20%
Prescription - Non-Preferred - Tier III	\$60	0%	0%	20%	20%
Hospital Services					
In-Patient Services	\$250	20%	40%	20%	40%
Out-Patient Services	\$100	20%	40%	20%	40%
Diagnostic Services	\$0	20%	40%	20%	40%
Emergency Care Services					
ER Visit, Urgent Care Center, Observation	\$100	0%	0%	20%	20%
Preventive Care Services					
Physical Exams / Preventive Care	\$0	0%	Not Covered	0%	Not Covered
Well Baby / Child Care Visits	\$0	0%	Not Covered	0%	Not Covered
Immunizations	\$0	0%	Not Covered	0%	Not Covered
Vision Screening	\$35	0%	40%	20%	40%
Hearing Screening	\$35	0%	40%	20%	40%

^{*} Above is a summary of common services - Please refer to the Schedule of Benefits for full details, limitations and exclusions



2010 P	lan Year - S	Schedule	of Benefits		
Covered Benefits	ARHealth			ARHealth HD PPO	
and Services*	In-Network Copayment	In-Network Coinsurance	Out-of-Network Coinsurance	In-Network Coinsurance	Out-of-Network Coinsurance
Allergy Services					
Injection with no office visit	\$0	20%	40%	20%	40%
Services by Specialty Providers (office visit & testing)	\$35	20%	40%	20%	40%
Ambulance Services					
Ground or Air Ambulance Transportation	\$0	0%	40%	20%	40%

- * Limited Benefit: \$2,000 per member per plan year
- * Includes both ground and air transportation

Behavioral / Mental Health & Substance Abuse Treatment Services

All services for behavioral health require preauthorization through LifeSynch 1-866-378-1645.

Traditional Out-Patient Services	\$25	0%	40%	20%	40%
In-Patient Services	\$250	20%	40%	20%	40%
Out-Patient Services (partial hospital / day treatment)	\$0	20%	40%	20%	40%
Out-Patient Services (Intensive Out- patient)	\$0	2 0%	40%	20%	40%
Residential Treatment	\$0	20%	40%	20%	40%
Dental Services					
Repair to non-diseased teeth due to accident/injury	\$35	20%	35%	20%	40%
Diabetes Management Service					
Insulin Pump & Supplies	\$0	20%	40%	20%	40%
Glucometers & Supplies	\$0	20%	40%	20%	40%
Diabetic Self Management Training	\$25	0%	40%	20%	40%

- Diabetic Supplies, Insulin, Insulin Syringes and Lancets (if purchased together) available through prescription drug card at your Pharmacy. Applicable charges may apply such as copayments, deductible charges, or coinsurance
- Glucometers must be purchased through DME provider and is not subject to annual maximum DME benefit

Durable Medical Equipment / Enteral	Feeding				
DME/Enteral Feeding	\$0	20%	40%	20%	40%

- Coverage is provided for medically necessary durable medical equipment, see exclusions
- Not all services require precertification and may be reviewed for medical necessity by AHH. Refer to page 14 for a current list of services
- Exclusion: The Plan does not provide benefits for DME that is for patient convenience
- Limited Benefit: \$10,000 per member per plan year

Apple Icon indicates Wellness Benefit paid at 100% by the Plan

Telephone Icon Indicates pre-authorization required, see page 14

Certain Limitations Apply - Please check your SPD Exclusions and Limitations section for more information.



Covered Benefits		ARHealth		ARHealt	h HD PPO
and Services*	In-Network Copayment	in-Network Coinsurance	Out-of-Network Coinsurance	In-Network Coinsurance	Out-of-Network Coinsurance
Emergency Care Services					
ER Visit, Urgent Care Center, Observation Services	\$100	0%	0%	20%	20%
 Visits deemed non-emergency charge page 71 of the glossary) 	d as hospital sei	rvices/outpatie	nt, the co-insuran	ce/copayment	will apply (see
Hearing Services					
Hearing Screening	\$35	0%	40%	20%	40%
* Limited Benefit: One screening every t	rree (3) years		<u> </u>		
Hearing Aid	\$0	0%	0%	20%	40%
* Limited Benefit: \$1400 per ear per three	(3) years				
Home Health Services					
Home Health Services	\$0	20%	40%	20%	40%
Home Intravenous Drugs					
Home IV Drugs and Solutions	\$0	20%	40%	20%	40%
Hospice Services					
Hospice Care	\$0	20%	40%	20%	40%
Hospital Services - Inpatient					
In-Patient Services	\$250	20%	40%	20%	40%
* Copayment charged per admission exc	•		•		
* If you select a private room, you are res	oonsible for the	difference in ch	arges for private r	oom and semi-	private room
Hospital Services - Outpatient					
Out-Patient Services	\$100	20%	40%	20%	40%
 Coverage is provided for medically necessary Not all services require precertification accurrent list of services Exclusion: The Plan does not provide b Limited Benefit: \$10,000 per member p 	and may be revi enefits for dural	ewed for medic	al necessity by AH	IH. Refer to pag	
Diagnostic Services	\$0	20%	40%	20%	40%
Immunizations					
immunizations	\$0	0%	Not Covered	0%	Not Covered
Maternity and Family Planning Service	es				
Prenatal and Postnatal Out-Patient Care	\$25	20%	40%	20%	40%
* Prenatal and Postnatal outpatient care					
In-Patient Maternity Services	\$250	20%	40%	20%	40%
 * Copayment applicable per admission * Hospital Length of Stay for Childbirth: any hospital length of stay in connection 					

 Hospital Length of Stay for Childbirth: This Plan complies with federal law that prohibits restricting benefits for any hospital length of stay in connection with childbirth for the mother and newborn child to less than 48 hours following a normal vaginal delivery or less than 96 hours following a caesarean section delivery


Apple Icon indicates Wellness Benefit paid at 100% by the Plan

Telephone Icon indicates pre-authorization required, see page 14

Certain Limitations Apply - Please check your SPD Exclusions and Limitations section for more information.



2010 PI	an Year - S	Schedule	of Benefits		
Covered Benefits	ARHealth			ARHealth HD PPO	
and Services*	in-Network Copayment	In-Network Coinsurance	Out-of-Network Coinsurance	in-Network Coinsurance	Out-of-Network Coinsurance
Ostomy Supplies					
Ostomy Supplies	\$0	20%	40%	20%	40%
* Limited Benefit: Not subject to DME lir	nit of \$1000	-		·- ···	
Pharmacy Benefit					
Prescription - Generic - Tier I	\$10	0%	0%	20%	20%
Prescription - Preferred - Tier II	\$30	0%	0%	20%	20%
Prescription - Non-Preferred - Tier III	\$60	0%	0%	20%	20%
Qualified OTC Programs	\$5	0%	0%	20%	20%
Professional Services					
Chiropractic Services	\$35	20%	40%	20%	40%
* Limited Benefit: Fifteen (15) visits per m	ember per Plan	Year			
Physician Office Visits	\$25	0%	40%	20%	40%
Speciality Care Services	\$35	0%	40%	20%	40%
 Includes such services as debridement without direct physican attention. 	and/or wound	dressing chang	es performed in	an out-patient s	etting with or
Physician Services provided under Out- Patient or In-Patient Care	\$0	20%	40%	20%	40%
Injectable Medication	\$0	20%	40%	20%	40%
Prosthetic and Orthotic Devices					
Prosthetic and Orthotic Devices and Services	\$0	20%	40%	20%	40%
Radiology Services					
Radiology Services	\$250	20%	40%	20%	40%



* Maximum of one (1) copayment per member per Plan Year

* Charges will not apply when provided in conjunction with Emergency Room or In-Patient Hospital Services

Rehabilitation Services (In-Patient)					
Rehabilitation Services	\$250	10%	40%	20%	40%

- * Limited Benefit: Sixty (60) days per member per Plan Year
- * Copayment applicable per admission. The limitation for no more than three in-patient admissionco-pays does not apply to rehab services


Rehabilitation Services (Out-Pati	ent)				
Physical Therapy	\$0	20%	40%	20%	40%
Occupational Therapy	\$0	20%	40%	20%	40%
Speech Therapy	\$0	20%	40%	20%	40%

Apple Icon Indicates Wellness Benefit paid at 100% by the Plan

Telephone icon indicates pre-authorization required, see page 14

Certain Limitations Apply - Please check your SPD Exclusions and Limitations section for more information.





Covered Benefits		ARHealth		ARHealt	h HD PPO
and Services*	In-Network Copayment	In-Network Coinsurance	Out-of-Network Coinsurance	in-Network Coinsurance	Out-of-Networ Coinsurance
Skilled Nursing Facility (SNF) Servi	ces				
SNF Services	\$250	10%	40%	20%	40%
* Limited Benefit: Sixty (60) days per i	member per Plan Ye	ear .			
Transplant Services					
Organ / Bone Marrow Transplant	\$250	20%	Not Covered	20%	Not Covered
 Copayment applicable per admission Limited Benefit: Two (2) organ trans Limited Benefit: \$10,000 lifetime lir conjunction with transplant service Coverage is provided for transplant Advantage at 1-800-482-8416 or No approved transplant providers and 	splants of the same nit for travel and ic s services subject to svasys Health at 1-1	odging determi	ned by EBD as rea tion by the benefi	sonable and no t coordinator (i	Health
Vision Care Services					
Vision Screening	\$35	0%	40%	20%	40%

Apple Icon indicates Wellness Benefit paid at 100% by the Plan

* Limited Benefit: One (1) exam every twenty-four (24) months

Telephone Icon indicates pre-authorization required, see page 14

Certain Limitations Apply - Please check your SPD Exclusions and Limitations section for more information.

DRAFT

Preventative Care / Wellness Benefits

The following preventative/wellness services are covered at 100% under the ARHealth and ARHealth HD PPO plans for employees and their covered dependents. Services are covered at In-Network providers ONLY. Services may be obtained from more than one physician. Services that are not for screening or preventative in nature, but rather due to illness or specific condition, may be subject to the standard Schedule of Benefits with co-payments, co-insurance, and deductibles when applicable. For questions, contact your Benefit Coordinator.

		· · · · · · · · · · · · · · · · · · ·		
Wellness Serv	vices			
Physical Exams	Adults (limit 1 per Plan Year at no cost)		
Routine Mammo	ogram (limit 1 per Plan Year at no cost)			
Annual Routine	Gynecological visit (limit 1 per Plan Yea	ar at no cost)		
New Baby/Well I	Baby Visits			
Initial comprehensive preventative medicine evaluation and management of an individual. Under 1 year Under 1 year Guidance/risk factor reduction interventions, and ordering of appropriate immunizations laboratory/diagnostic, new patient; infant (age under 1 year)				
Periodic comprehensive preventative medicine reevaluation and management of an individual. Under 1 year				
Newborn Care	Normal newborn care in other than hospital or hirthing room setting, including physical			
Preventative Car	re Services - Child (under age 18)			
• Birth to Age 1	= Six Visits	• Age 12 to 17 = Annual Visits		
• Age 1 to 2 = Th	nree Visits	Lead Level = Age 9 months to 24 months		
• Age 3 to 4 = A	nnual Visits	• Vision Screening = 3-6, 8, 10, 12 & 15 months		
• Age 5 to 11 = /	Annual Visits	• Hearing Screenings = 4-6, 8, 10, 12 & 15 months		
Preventative Ca	re Services - Adults (age 18 and over)			
Annual Physics	al Office Visit	Fecal occult blood test annually and one of the		
Colorectal Cancer Screening beginning at age 50		following: * Sigmoidoscopy every 5 years * Colonoscopy once every 10 years * Double contrast barium enema once every 5 years		
• Pap Smear		 Cholesterol and HDL - Once every 5 years for males age 35 and older and once every 5 years for females 45 and older 		
 Prostate Specific Antigen (PSA) age 40 and over 				

^{*}The Arkansas Health Department is considered an In-Network provider for adult and child immunizations

Preventive Care / Wellness Benefits continued...

Immunizations - Child (under age 18) Diphtherla Diphtheria and Tetanus toxoid and acellular pertussis (DTaP) Diphtheria and Tetanus toxoid and whole cell pertussis (DTP) Diphtheria and Tetanus toxoid and whole cell pertussis and Hemophilus Influenza b (DTP-Hib) Diphtheria and Tetanus toxoid and whole cell pertussis, Hemophilus Influenza b, and Inactivated Poliovirus (DTap-Hib-IPV) Diphtheria and Tetanus toxoid for ages over 7 (Td) Gardasil ages 9 to 18 Hemophilus Influenza b (hib) Hepatitis B (HEP B) Hepatitis B (HEP B) and Hemophilus Influenza b (hib) combo Hepatitis C Influenza (flu) ages 6 months and older Measles, live for subq use (IPV) Measles, Mumps, Rubella (MMR) Measles, Mumps, Rubella and Varicella (MMRV) Measles, Rubella Menactra Vaccine ages 11 to 18 Mumps Pneumococcal Vaccine Polio, live, oral use (OPV) Rota Teq Vaccine administered orally in 3 doses for the prevention of Rotavirus, ages 2, 4, and 6 months Rubella Tetanus Varicella Immunizations - Adults (age 18 and over) Diphtheria, every 10 years Diphtheria and Tetanus toxoid for ages over 7 (Td), every 10 years Gardasil ages 18 to 26 Hepatitis B (HEP B) - once per lifetime Hepatitis Cages 18 to 24 Influenza (flu), annually Menactra Vaccine ages 18 to 27 Pneumococcal Vaccine Tetanus, Diphtheria, and Pertussis - single dose Tdap, adults 19 to 64 Zostavax Vaccine for adults 60 and over